Aruna Bio, a US-based company that deals with the development of neural exosomes for the treatment of neuro-inflammatory and neurodegenerative diseases, announced on Wednesday that it has named Stephen From as its new chief executive officer (CEO).

From succeeds Skip Irving who served as interim CEO and who will continue to serve on the Aruna Bio board of directors. From has held the position of CEO and chairman of EyeGate Pharmaceuticals. His experience includes drug delivery, clinical development, and working with the FDA. He has served in investment banking for Bank of America and Robertson Stephens.

Skip Irving, Aruna Interim CEO and director, said, 'The Aruna Bio board of directors would also like to thank Dr Mark Sirgo for his leadership of the company over the last three years. Mark provided valuable leadership to the company during his tenure.'